THE CHROMOSOME | Clinical Content Series
Growth Hormone Deficiency
Back to Case Studies ArchiveCase Study
He was 47 years old and described his body as having simply given up. That was his exact phrase, given up. He had been athletic in his thirties. He had maintained a reasonable weight without particular effort for most of his adult life. Then, across a period of roughly four years, everything had changed. The muscle had gone first, not dramatically, but steadily, the way a tide retreats. Then the fat had arrived, settling around his abdomen in a way that felt foreign, almost imposed, as though it belonged to someone else's body. His recovery from any physical exertion had become painfully slow. His sleep was shallow and unrefreshing. His skin had lost its tone. He looked, he told me, ten years older than he had four years ago.
He had been told it was simply the ageing process. He had been told to accept it.
I do not accept ageing as a diagnosis when a treatable hormonal deficiency is present.
When I evaluated his growth hormone axis the picture was unambiguous. His IGF-1, the primary mediator of growth hormone action, was severely depressed for his age. His growth hormone stimulation testing confirmed deficiency. This was not the normal gradual decline of growth hormone with age. This was pathological adult onset growth hormone deficiency, a clinically significant endocrine condition that produces a constellation of metabolic consequences almost identical to accelerated ageing and is almost never investigated in Pakistani adults.
Growth hormone is not simply the hormone of childhood growth. In adults it is a critical metabolic regulator, governing the balance between muscle and fat, the quality of sleep, the rate of cellular repair, the integrity of cardiovascular function, and the efficiency of every anabolic process in the body. When it is deficient in an adult, the body shifts its composition toward fat and away from muscle, the metabolism slows, sleep quality deteriorates, and the entire biological machinery of recovery and repair operates below capacity.
The FTO gene's influence on hypothalamic somatotroph function, the cells that produce growth hormone releasing hormone, creates a predisposition in Pakistani patients to earlier and more pronounced growth hormone decline than Western populations experience. I have observed this pattern consistently across Pakistani men and women presenting with the combination of unexplained visceral obesity, accelerated physical ageing, and profound fatigue that characterises adult growth hormone deficiency.
We addressed his growth hormone deficiency through a carefully calibrated protocol. We simultaneously treated his insulin resistance, which had been suppressing growth hormone pulsatility independently, and his visceral fat load, which had been amplifying somatostatin tone and further inhibiting growth hormone release. The interventions worked together rather than in isolation because in THE CHROMOSOME protocol they are always designed to.
Fourteen months later he had lost 24 kilograms of fat and gained measurable lean muscle mass simultaneously, a combination that is biologically impossible through diet and exercise alone in a growth hormone deficient patient. His sleep had transformed. His skin had improved. His energy had returned to a level he had not experienced in years.
He had not simply been ageing. He had been deficient. And deficiency, unlike ageing, can be treated.
FAQs
Adult growth hormone deficiency is a recognised endocrine condition in which the pituitary gland produces insufficient growth hormone to maintain normal adult metabolic function. In adults, growth hormone governs the balance between muscle and fat tissue, the quality and depth of sleep, cardiovascular health, cellular repair, and metabolic rate. Its deficiency produces progressive visceral obesity, muscle loss, fatigue, poor sleep, and accelerated physical ageing, a combination almost universally attributed to lifestyle or normal ageing in Pakistani clinical practice. Growth hormone stimulation testing is rarely performed in Pakistani adults because the condition is not considered. Dr. Zaar evaluates the growth hormone axis in every patient presenting with this clinical pattern precisely because its absence from standard diagnostic thinking produces systematic underdiagnosis.
Growth hormone exerts a direct lipolytic effect on adipose tissue, it actively stimulates the breakdown and release of stored fat for energy. In its absence, fat accumulation accelerates and fat release is suppressed simultaneously. The effect is most pronounced in visceral fat, the deep abdominal fat surrounding the organs, because visceral adipocytes are particularly sensitive to growth hormone signalling. Simultaneously, the muscle loss that accompanies growth hormone deficiency reduces resting metabolic rate, further promoting fat storage. Pakistani patients with growth hormone deficiency gain visceral fat progressively and lose muscle steadily, producing a body composition shift that no dietary intervention can meaningfully reverse without addressing the hormonal deficiency driving it.
The FTO gene at Chromosome 16q12.2 influences hypothalamic regulation of growth hormone releasing hormone, the signal that drives pituitary growth hormone production. In Pakistani patients, the FTO associated metabolic profile creates a predisposition to earlier and more pronounced somatotroph dysfunction, meaning the growth hormone axis begins to decline at a younger age and with greater metabolic impact than Western clinical literature anticipates. Dr. Zaar's clinical observation of Pakistani patients with visceral obesity consistently identifies growth hormone axis impairment as a contributing factor that is amplified by the FTO associated baseline, producing a more severe metabolic picture than the degree of obesity alone would predict.
Insulin resistance and growth hormone deficiency exist in a bidirectional suppressive relationship that accelerates metabolic deterioration in Pakistani obesity patients. Chronically elevated insulin, the hallmark of insulin resistance, directly suppresses growth hormone pulsatility by enhancing somatostatin tone in the hypothalamus. Somatostatin is the inhibitory signal that switches off growth hormone release. High insulin keeps this switch in the off position continuously, further deepening the growth hormone deficiency that is simultaneously worsening the insulin resistance. Visceral fat amplifies this cycle by releasing free fatty acids and inflammatory cytokines that independently suppress pituitary growth hormone secretion. THE CHROMOSOME protocol addresses insulin resistance as a prerequisite to growth hormone axis restoration, because the two cannot be treated in isolation.
The majority of daily growth hormone secretion occurs during slow wave sleep, the deepest and most restorative stage of the sleep cycle. In growth hormone deficient patients, this relationship operates in reverse, not only is growth hormone failing to be produced during sleep, but the deficiency itself disrupts slow wave sleep architecture, producing shallower, less restorative sleep that further suppresses growth hormone pulsatility. Pakistani patients with this pattern describe sleep that never feels adequate regardless of duration, waking unrefreshed, fatigued throughout the day, and unable to recover from physical or mental exertion. Restoring sleep architecture is a clinical priority in THE CHROMOSOME protocol for growth hormone deficient patients, because without deep sleep, hormonal restoration is incomplete regardless of other interventions.
Adult growth hormone deficiency is a treatable endocrine condition, and treatment produces measurable and significant improvements in body composition, metabolic function, sleep quality, cardiovascular health, and psychological wellbeing. In Dr. Zaar's protocol, treatment begins with addressing every suppressible cause of growth hormone impairment, insulin resistance, visceral fat load, sleep disruption, and cortisol excess, before considering direct growth hormone intervention. Where peptide based secretagogues are clinically appropriate, they are incorporated into the comprehensive protocol as part of a coordinated hormonal restoration strategy. THE CHROMOSOME protocol does not treat growth hormone deficiency as an isolated finding. It treats it as one component of a hormonal network that must be restored in its entirety.
Growth hormone plays a critical role in maintaining cardiovascular structure and function, it governs cardiac muscle contractility, endothelial integrity, lipid metabolism, and inflammatory regulation within the vascular system. Its deficiency produces a cardiovascular risk profile characterised by elevated LDL cholesterol, reduced HDL cholesterol, increased visceral fat, impaired endothelial function, and low grade systemic inflammation, all of which are independently associated with accelerated atherosclerosis and cardiovascular disease. In Pakistani patients, who already carry a genetically influenced predisposition to cardiovascular risk through the FTO associated metabolic profile, growth hormone deficiency adds a significant additional burden that is almost never recognised as a treatable hormonal cause of cardiovascular deterioration.
The symptomatic profile of adult growth hormone deficiency, profound fatigue, low mood, reduced motivation, social withdrawal, impaired concentration, loss of physical vitality, and deteriorating body composition, overlaps almost completely with clinical depression and is culturally attributed to the pressures of middle age in Pakistani men. Physicians who do not consider the hormonal axis prescribe antidepressants or reassure the patient that what he is experiencing is normal for his age. Neither intervention addresses the growth hormone deficiency, which continues to worsen, deepening the metabolic deterioration and the psychological consequences simultaneously. Dr. Zaar measures IGF-1 and evaluates the growth hormone axis in every Pakistani man presenting with this clinical picture, because the difference between ageing and deficiency is a blood test and the right question.